Report
Valens Research

Weekly Equity Idea Highlight - 2018 11 28

Market expectations for PINC are currently very pessimistic. The market is expecting
UAFRS-based (Uniform) ROA (ROA') to fade from 78% in 2018 to 43% in 2023, with Uniform Asset growth slowing to 10% a year going forward. The market appears to be concerned about their legacy GPO business and competition there, while the company has been focused on building other businesses around their GPO business, to defend that moat and expand to higher value add services.

Management specifically is focused into moving into higher value add areas that are in high demand, such as around value based care initiatives and clinical informatics to identify better outcomes for patients. Analysts appear to recognize that these initiatives are working. While the market has been worried about collapsing ROA', the company actually is forecast to see ROA' rise to 70%+ levels going forward, showing the acceleration this strategy is having for the company, which points to fundamental upside.

Management communication also gives reason to believe the company is seeing stronger execution than the market is recognizing. During the Q1 call, management showed confidence across their business, including about new products and business they had acquired, their success in diversifying their revenue base, and about improved visibility for their revenue for investors. This was in line with the Q3 and Q4 calls, where management also showed confidence about innovating new offerings and generating more revenue from their customers, and around their share buyback initiatives.

Considering low market expectations, positive strategic tailwinds, management's intelligent strategy, and strong positive fundamental momentum for the company based on management's communication, there appears to be material near-term and long-term equity upside for PINC.
Underlying
Premier Inc. Class A

Premier is a holding company. The company, together with its subsidiaries and affiliates, is a healthcare performance improvement company. The company provides technology-enabled platform that provides supply chain services, clinical, financial, operational and value based care software-as-a-service informatics products, consulting services and performance improvement collaborative programs. The company has two business segments: Supply Chain Services, which assists its members in managing their non-labor expense and capital spend through a combination of products, services and technologies; and Performance Services, which provides information technology analytics and workflow automation and consulting services.

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch